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Background/Aims: To assess the effectiveness and the safety of radio-frequency thermal ablation (RFTA) in patients
with hepatocellular carcinoma (HCC) %5 cm in compensated cirrhosis.
Methods: A cohort of 202 consecutive patients (165 Child-Pugh class A and 37 class B) was prospectively assessed. A
single lesion was observed in 160/202 (79.2%), two lesions in 29/202 (14.3%), and three lesions in 13/202 (6.4%) of
patients.
Results: Sixty-seven patients died. Survival rates were 80% at 12 months, 67% at 24 months and 57% at 30 months
(Child-Pugh A 59% and Child-Pugh B 48%). By Cox regression analysis, survival was independently predicted by
serum albumin levels R35 g/L, platelet count R100.000/mmc, tumor size %3 cm, complete response at 1 month and
Barcelona Clinic Liver Cancer (BCLC) staging classification. Overall recurrence rates were 22, 38, and 44% at 12, 24,
and 30 months, respectively. One procedure-related death occurred. The proportion of major complications after
treatment was 3.9%.
Conclusions: A complete response after RFTA significantly increases survival. The longest survival is obtained in the
presence of HCC %3 cm and of higher baseline albumin levels and platelet counts. BCLC staging classification is able
to discriminate patients with good or poor prognosis.
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The 5-year survival rate of patients with hepatocellular
carcinoma (HCC) %5 cm undergoing surgical or percuta-
neous ablation is lower than 50% because of the high risk of
local recurrence particularly after percutaneous ablation, as
well as the occurrence of new lesions in the liver even
though treatment has been considered potentially curativeJournal of Hepatology 42 (2005) 535–540www.elsevier.com/locate/jheplished by Elsevier B.V. All rights reserved.
C. Camma` et al. / Journal of Hepatology 42 (2005) 535–540536[1–3]. In 2000, the European Association for the Study of
the Liver (EASL) Monothematic Conference on Clinical
Management of HCC [4] concluded that radio-frequency
thermal ablation (RFTA) was not recommended as the
standard percutaneous technique because of its higher rate
of side effects and lower applicability of treatment due to
tumor location, when compared to percutaneous ethanol
injection (PEI). Since then, a small randomized controlled
trial (RCT) showed that RFTA was superior to PEI with
respect to local recurrence-free rates [5].
The primary aim of this prospective study was to assess
the effectiveness and the safety of RFTA and to identify
predictors of survival by multivariate analysis in a cohort of
patients with HCC %5 cm in compensated cirrhosis.2. Patients and methods2.1. Patients
From January 1999 to September 2003, 531 consecutive patients with
HCC %5 cm were screened and 202 were treated by RFTA at the three
referral speciality units involved in the study. We used the following
inclusion criteria for RFTA: (a) age O65 yr, or age ! 65 yr in patients who
refused surgery or orthotopic liver trasplantation or with associated diseases
contraindicating surgery; (b) a single HCC 5 cm in diameter or smaller or as
many as three HCCs each 3 cm in diameter or smaller; (c) cirrhosis
classified as Child-Pugh class A or B [6]; (d) absence of portal vein
thrombosis or extrahepatic metastases; (e) platelet count O40,000/mm3;
prothrombin time ratio O40%. Exclusion criteria were age over 75 years,
tumors O5 cm, extrahepatic metastases, portal vein thrombosis, ascites, or
dilated bile ducts, cardiac arrhythmia. No exclusion criteria were related to
the location of tumors for all patients in Child-Pugh class A. By contrast,
patients in Child-Pugh B class in whom the tumor was not treatable by
percutaneous approach were excluded from RFTA.
We used a commercial ultrasound (US) scanner (ESAOTE biomedica
AU5) with a guide device. Before starting the procedure, all the patients
were staged with spiral computed tomography (CT) scan, alfa-fetoprotein
(AFP), and chest X-ray. The mean time elapsed between HCC diagnosis
and the RFTA procedures was 1 month.
The study was approved by the local ethics committee and a written
informed consent was obtained from all patients.2.2. Outcomes and follow-up
One month after RFTA, a spiral CT scan was repeated and the AFP
level was measured. Complete response was defined as no evidence of
neoplastic disease and no evidence of new lesions at spiral CT one month
after treatment. When there was evidence of tumor persistence, a second
RFTA was performed. Treatment failure was defined as the presence of
viable tumor at the end of therapy. The follow-up protocol included clinical
assessment, measurements of liver function by Child-Pugh score, routine
laboratory investigations, AFP level, US examination every 3 months, and
abdominal spiral CT scan every 6 months.
Local recurrence, after total necrosis by spiral CT scan, was defined as
the development of tumor staining at the margin of the tumor or
enlargement of the tumor on a follow-up spiral CT. When an enlargement
of the size of lesion, or a new lesion, was observed during US examination
or an increase of 100 ng/mL AFP levels with respect to previous assay was
found, a CT scan was performed. If local recurrence was detected, RFTA
was repeated.
A separate new lesion in the liver (i.e. distant recurrence) was
considered to have developed when there was the appearance of another
focal lesion distinct from the treated one (i.e. a new nodule that arose more
than 2 cm from the original lesion). In this case, a second RFTA wasundertaken. Patients who developed diffuse HCC (i.e. more than 3 hepatic
lesions) were not retreated.
2.3. RFTA technique
All treatments were performed only on inpatients under conscious
sedation. RFTA was performed under ultrasound guidance with a 50 W
electrical generator (Model 500 L; RITA Medical System, Mountain View,
Calif.) connected to an expandable 15-gauge, 25.0-cm-long electrode with
a 1.0-cm-long exposed tip (expandable by means of four hooks) until
December 31 1999, and then with a 150 W generator (Model 1500 L; RITA
Medical System, Mountain View, Calif.) connected to an expandable 15–
14-gauge electrode with a 2.0-cm-long exposed tip (expandable by means
of seven, or nine, hooks).
This electrode was placed into the center of the lesion maintaining the
temperature of the needle tip at 100 8C or more for 10–12 min. When
necessary due to tumor size, several insertions of the needle electrodes to
treat overlapping zones were needed to complete the procedure, though
never more than three insertions per procedure. Inclusion criteria for RFTA
during laparotomy were: (a) cirrhosis Child-Pugh class A and (b) any
location of tumors that precluded the percutaneous approach.
2.4. Statistical evaluation
The primary outcome of the study was overall survival. The secondary
outcomes were: (a) overall recurrence defined as any appearance of the
tumor (i.e. local recurrence or separate new lesions in the liver or
extrahepatic metastases) during follow-up; (b) development of separate
new lesions in the liver; (c) local recurrence. The Kaplan-Meier method [7]
was used to estimate survival, overall recurrence, development of separate
new lesions and of local recurrence. Differences in the survival rate were
assessed by the log-rank test. The observed survival time was the interval
between starting RFTA and death or the final follow-up. For overall
recurrence, the tumor-free time was the interval between no evidence of
neoplastic disease at spiral CT one month after the treatment and the
appearance of the tumor. In this analysis, the follow-up of patients dying
without recurrence was censored at the time of death, and these patients
were classified as cancer-free. The following variables at baseline were
considered for univariable analysis: participating centres, age, sex, anti-
HCV positivity, HBsAg positivity, alcohol abuse, bilirubin level, albumin
level, prothrombin activity, platelet count, creatinine levels, tumor size,
number of neoplastic lesions, AFP level, complete response to treatment,
and Barcelona Clinic Liver Cancer (BCLC) staging classification.
Variables with a P value !0.05 at univariable analysis were included in
the final multivariable model. The Cox model [8] was used to identify the
risk factors for overall survival, appearance of separate new lesions and
occurrence of local recurrence in a multiple regression analysis. All
analyses were conducted with SAS [9].3. Results
3.1. Features of patients at baseline
Seventy-four subjects out of 202 (36.6%) were over 70
years of age. In all patients, HCC was associated with
cirrhosis. Diagnosis of HCC was biopsy-proven in 158/202
subjects (78.2%) and based on noninvasive diagnosis of
HCC in 44/202 (21.8%), according to international criteria
[4]. The median value of AFP was 18 ng/mL. Sixteen
subjects only had AFP value O400 ng/mL.
A single lesion was observed in 79.2%, two lesions in
14.3% and three lesions in 6.4% of patients (Table 1). The
tumor size was %3 cm in 165/202 (81.6%) of the patients.
Only in 5/202 (2.4%) a negligible amount of ascites was
detected by ultrasound. At presentation 85 out of 202
Table 1
Baseline features of 202 patients with hepatocellular carcinoma in
compensated cirrhosis treated with RFTA according to Child-Pugh
class
Characteristics Child-Pugh A
(nZ165)
Child-Pugh B
(nZ37)
P Value
Age (yrs) 66.8G8.2 67.4G6.9 0.61
Male sex—no.
(%)
108 (65.4) 23 (62.1) 0.70
Anti-HCV posi-
tivity—no. (%)
119 (72.1) 23 (62.1) 0.23
HbsAg positiv-
ity—no. (%)
26 (15.7) 11 (29.7) 0.04
Alcohol abuse 16 (9.6) 5 (13.5) 0.99
Alfa-Fetoprotein
(ng/mL)
128G364.5 419.9G922.9 0.43
PLT X 103/mmc 113.8G34.4 96.5G41.5 0.02
Serum albumin
(g/L)
37.9G4.7 33.8G5.4 0.0001
Prothrombin
activity (%)
86.8G16.8 74.6G16.4 0.008
Serum bilirubin
(mg/dl)
1.10G0.6 1.85G0.9 0.0001
Creatinine levels
(mg/dl)
0.94G0.37 0.89G0.25 0.56
Esophageal vari-
cesa —no. (%)
62/130 (47.6) 14/30 (46.6) 0.75
Number of lesion—no. (%)
Single lesion 126 (76.3) 34 (91.8) 0.08
Two lesions 26 (15.7) 3 (8.1)
Three lesions 13 (7.8) 0 –
Tumor size—no. (%)
%3 cm 137 (83.0) 28 (75.6) 0.29
O3 cm 28 (16.9) 9 (24.3)
BCLC Staging Classification—no. (%)
A1 73 (44.2) 12 (32.4) 0.84
A2 43 (26.0) 10 (27.0)
A3 10 (6.0) 12 (32.4)
A4 26 (15.7) 1 (2.7)
B 13 (7.8) 2 (5.4)
Abbreviation: plus–minus values are meansGSD.
a Assessed in 160 patients.
Table 2
Follow-up of 202 patients with hepatocellular carcinoma in compen-
sated cirrhosis treated with RFTA according to Child-Pugh class
Characteristics Child-Pugh
A (nZ165)
Child-Pugh
B (nZ37)
Total
(nZ202)
Complete response
After one cycle (%) 135 (81.8) 29 (78.3) 164 (81.1)
After two cycles (%) 17 (10.3) 6 (16.2) 23 (11.3)
Treatment failure (%) 13 (7.8) 2 (5.4) 15 (7.4)
Mean follow-up (moGSD) 19.5G13.8 17.8G17.0 19.2G14.4
Cancer recurrence—no. (%) 56 (33.9) 8 (21.6) 64 (31.6)
Local recurrence—no. (%) 17 (10.3) 2 (5.4) 19 (9.4)
New lesions—no. (%) 33 (20) 3 (8.1) 36 (17.8)
Local recurrence plus new
lesion—no.(%)
3 (1.8) 1 (2.7) 4 (1.9)
Metastases—no. (%) 3 (1.8) 2 (5.4) 5 (2.4)
RFTA retreatment—no. (%) 40 (24.2) 6 (16.2) 46 (22.7)
New lesion 26 (15.7) 5 (13.5) 31 (15.3)
Local recurrence 14 (8.4) 1 (2.7) 15 (7.4)
Major complications—no. (%) 3 (1.8) 5 (13.5) 8 (3.9)
Death—no. (%) 52 (31.5) 15 (40.5) 67 (33.1)
Abbreviation: plus–minus values are meansGSD.
Fig. 1. Cumulative survival in all patients treated with radiofrequency
thermal ablation for hepatocellular carcinoma and according to Child-
Pugh class A and Child-Pugh class B. [This figure appears in colour on
the web.]
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15 patients (7.4%) scored BCLC B, so for statistical
purposes they were pooled with BCLC A4 in the survival
analysis.
3.2. Follow-up
The mean length of follow-up after RFTA was 19.2G
14.4 months (median 15 months, range 1–60 months) for the
entire group. Twelve out of 202 subjects (5.9%) were lost
during follow-up visit. Their main baseline features did not
differ significantly from the whole series of patients. During
follow-up a total of 67 deaths occurred (Table 2). Among
the 67 deaths only 8 patients (11.9%) died cancer-free (i.e.
without local recurrence, new lesions or distant metastases),
while among the remaining 59 patients 11 subjects had a
cancer progression and 48 subjects had a cancer recurrence.
The final causes of death were liver failure in 45 patients,variceal bleeding in 9, spontaneous bacterial peritonitis in
4, hemoperitoneum in 4, cachexia in 3, and unknown causes
in 2.
The overall survival rates (Fig. 1) were 80% (95%CI 74–
86), 67% (95%CI 60–76), and 57% (95%CI 48–66) at 12,
24, and 30 months, respectively, without a significant
difference among the three participating centres (PZ0.24
by log-rank test). Survival was longer among Child-Pugh A
class patients (83, 69 and 59% at 12, 24, and 30 months,
respectively) than among Child-Pugh B class patients (66,
60, and 48% at 12, 24, and 30 months, respectively) (P 0.19
by log-rank test). Survival was significantly longer in the
subgroup of 85 potentially resectable patients, all in BCLC
A1 stage, in comparison with all others (PZ0.004 by log-
rank test).
Multivariate model, which considered baseline albumin
levels, platelet counts, AFP, tumor size, complete response
and BCLC staging classification, indicated that all variables,
but AFP, were independent and significant predictors of
overall survival (Table 3).
Table 3
Adjusted relative risk for death in 202 patients with hepatocellular carcinoma in compensated cirrhosis treated with RFTA
Variable Code b S.E. P Value Relative risk (95% CI)
Serum albumin 0:!35 g/L K0.56 0.26 0.03 0.57 (0.33–0.96)
1: R35 g/L
Platelet count 0: S100.000/mmc 0.57 0.27 0.03 1.76 (1.03–3.03)
1: !100.000/mmc
Tumor diameter 0:%3 cm 0.69 0.24 0.005 1.99 (1.22–3.26)
1:O3 cm
BCLC staging classi-
fication
0: A1 0.25 0.11 0.02 1.28 (1.02–1.61)
1: A2
2: A3
3: A4/B
Complete response 0: No K1.7 0.38 0.0001 0.18 (0.085–0.39)
1: Yes
Adjusted for baseline alfa-fetoprotein levels.
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follow-up: 40 patients developed new lesions in the liver, 23
subjects developed a local recurrence, and in 5 subjects
distant metastases were detected (Table 2). The cumulative
overall recurrence-free rate (until separate new lesions,
local recurrence or extrahepatic metastases occurred) is
shown in Fig. 2. Overall recurrence rates were 22% at 12
months, 38% at 24 months and 44% at 30 months. Upon
multivariate analysis, only platelet counts lower then
100.000/mmc (relative risk 2.90, 95% CI 1.62–5.21) was
an independent risk factor for overall recurrence.
A total of 40 patients developed new lesions in the liver.
The 12-, 24-, and 30-month rate of occurrence of separate
new lesions was 13, 24, and 30%, respectively (Fig. 3). In 31
out of 40 patients (77.5%) who developed a separate new
lesion, a second RFTA was performed. Only platelet counts
lower then 100.000/mmc proved to be an independent risk
factor for the occurrence of new lesions (relative risk 2.85,
95% CI 1.46–5.53) by multivariate analysis.
In 92.5% (187/202 patients) of cases, a complete
response was achieved; in 87.7% of these patients
(164/187) the complete tumor necrosis was achieved after
one treatment; and in 12.3% (23/187), after two treatments.Fig. 2. Cumulative overall recurrence-free rate in all patients treated
with radiofrequency thermal ablation for hepatocellular carcinoma.In the remaining 7.5% (15/202) of patients, the tumor was
still viable after two cycles of RFTA. We did not find a
significant difference among the three participating centres
in the rate of complete tumor necrosis (PZ0.42). In
contrast, the overall rate of complete tumor necrosis
achieved after one treatment was significantly higher for
tumors %3 cm in diameter (139/165, 84.2%) than for those
O3 cm in diameter (26/37, 70.2%) (PZ0.047).
In 23/187 patients (12.3%), a local recurrence was
observed, and in 15 of those (65.2%), a second RFTA was
performed. The 12-, 24-, and 30-month rate of local
recurrence was 10, 16, and 19%, respectively (Fig. 3).
None of the baseline variables analyzed were significantly
associated with the occurrence of local recurrence.
3.3. Treatment safety
One treatment-related death was observed in a patient 4
weeks after RFTA due to liver failure following surgical
resection for intestinal perforation. The proportion of major
complications after treatment was 3.9%. Three patients
developed portal vein thrombosis soon after treatment.
Other major reported complications were subcapsular
hematoma (1 case), intrahepatic abscess (1 case) and pleural
effusion (3 cases). The overall rate of post-treatment adverseFig. 3. Rate of occurrence of distant and local recurrence in patients
with hepatocellular carcinoma treated with radiofrequency thermal
ablation. [This figure appears in colour on the web.]
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patients (5/37, 13.5%) than in those in Child-Pugh A class
(3/165, 1.8%) (P!0.001).
None of the treated patients experienced either needle-
track seeding or peritoneal hemorrhage. Minor compli-
cations were reported in 10/202 (4.9%) patients. The three
most frequent minor complications after treatment were
pain requiring major analgesia, transient episode of fever
and skin burns.
3.4. Subgroup analysis of patients who underwent RFTA
during laparotomy
RFTA was performed during laparotomy in 52/202
patients (25.7%), all in Child-Pugh A class. Their main
baseline features did not differ significantly from the whole
series of Child-Pugh A class patients. RFTA was performed
during laparotomy because the tumor was not treatable by
percutaneous approach (location near of main vascular
vessels, portal branches or perihiliar hepatic region) in
10/52 patients (19.2%), because the tumor was located in
the surface of the liver in 20/52 (38.4%) and because tumor
location was near the stomach, the colon, the gallbladder or
the heart in 14/52 subjects (26.9%). In the remaining 8
patients (15.3%), the nodule was preoperatively judged
resectable, but RFTA was evaluated as safer than surgical
resection during laparotomy. Treatment-related death as
well as major complications were not observed. In all
patients, treated during laparotomy a complete tumor
necrosis was achieved. No significant difference was
observed in the local recurrence rate between patients
treated during laparotomy (5/52; 9.6%) and those treated
percutaneously (18/150; 12%) (PZ0.64). Overall survival
did not differ significantly between Child-Pugh A class
patients who underwent RFTA percutaneously and those
who underwent RFTA during laparotomy (PZ0.34).4. Discussion
To our knowledge, the findings in the current study,
evaluating the impact of RFTA on a large cohort of patients
with HCC %5 cm in diameter in compensated cirrhosis,
represents the largest prospective cohort study to date. In the
present study, the 30-month overall survival rate was 57%.
This reported value for efficacy is in keeping with the 2-year
survival of 63% observed in our previously published study,
in which patients with similar characteristics were treated
with PEI [10]. Only one small RCT reported that RFTA was
superiot to PEI with respect to local recurrence-free survival
rates [5].
Lencioni et al. [5] failed to identify any predictor
significantly associated with survival after RFTA. We did
not confirm the observation of Giovannini [11] suggesting a
better survival after RFTA in patients who develop HCC
after alcoholic cirrhosis compared to those in whom HCCoccurs after viral cirrhosis. Our study shows that patients
with HCC and no advanced liver disease, assessed by high
baseline albumin and platelet levels, may benefit from
RFTA treatment. The finding that high baseline albumin
level was associated with improvement in survival is in
agreement with the results of our previous study on PEI
[10], as well as those of the study by Castellano [12].
Although a limitation to our study is the lack of data on
direct assessment of portal hypertension [13], an interesting
finding was the observation that platelet counts, a well
known surrogate marker of clinically relevant portal
hypertension, proved to be a strong predictor of survival.
Finally, a cancer-related variable, such as the tumor size,
emerges as an independent predictor for better survival upon
multivariate analysis.
The antitumor effect of RFTA has been substantiated by
this study showing a complete response rate of 92%. This
reported value for complete response is in keeping with the
results reported in the literature, ranging from 85 [14] to
91% [5]. From the present study, it seems that overall
survival strictly depends from the achievement of a
complete tumor necrosis, suggesting that the achievement
of a complete response should be carefully assessed by CT
scan in all patients after RFTA. However, histologic data
supporting radiologic assessment of complete response are
lacking, suggesting that local recurrence could be inter-
preted as failure to provide adequate local control of HCC,
particularly when viable tumor was detected within 6
months from treatment in spite of a radiologic assessment of
complete response one month after treatment.
Our study shows that the BCLC staging classification
sensitively identifies patients with HCC with a good or
unfavorable prognosis. This clinical staging system is
simple and represents a valuable tool for the prognostic
evaluation of the patient, particularly in the setting of early
tumors. It is important to underscore that the 12 Child-Pugh
B7 patients classified as BCLC A1 included in this study
were a very well compensated subgroup of subjects with
normal serum bilirubin, serum albumin levels between
35 and 30 g/L and prothrombin activity between 70 and
50%, all without clinically relevant portal hypertension.
An important finding in the present study was the high
rate of appearance of new lesions in the liver. The 3-year
occurrence of new lesions in our series (34%) was quite
similar to that of our previous study on PEI (41%), as well as
that found in the study by Lencioni [5], in which the 2-year
recurrence rate of patients treated by RFTA was 36%. Only
baseline platelet counts were found upon multivariate
analysis to independently predict the development of new
lesions in the liver.
In about 25% of patients, we were unable to perform
RFTA by percutaneous approach due to tumor location. In
these cases, RFTA was performed during laparotomy, thus
increasing costs and limiting the applicability of RFTA,
particularly when compared to PEI. However, treatment-
related death as well as major complications were not
C. Camma` et al. / Journal of Hepatology 42 (2005) 535–540540observed in this subgroup of patients and the reported value
for survival was similar to that of Child A class patients
treated by a percutaneous approach, indicating that RFTA
performed during laparotomy is a safe and efficacious
procedure.
A recent large multicenter retrospective study [15]
reported a low rate (0.5%) of seeding after thermal ablation
of HCC or colorectal metastasis. Indeed, Lencioni et al. [5]
did not observe any case of tumor seeding after RFTA. Our
study, confirming the observation of Lencioni and col-
leagues [5], provides further evidence that the risk of
seeding is very low during follow-up.
In this study, one procedure-related death was observed
and additional major complications occurred (portal vein
thrombosis, pleural effusions, intrahepatic abscess and
subcapsular hematoma) in about 4% of patients. We
observed that the overall rate of post-treatment major
adverse events was significantly higher in Child-Pugh B
class patients than in those in Child-Pugh A class.
The available evidence is sufficient to conclude the
following: (1) a complete response after RFTA significantly
increases survival; (2) the overall survival rate after 30
monts of follow-up remains low (57%) because of the high
rate of recurrence; [3] a tumor size O3 cm and low baseline
albumin and platelet levels significantly increase the risk of
death; BCLC staging classification is able to discriminate
patients with good or poor prognosis; [4] the applicability of
percutaneous RFTA may be restricted in about 25% of
patients by tumor location. RFTA performed during
laparotomy is an effective and safe procedure.Acknowledgements
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